Cargando…
Multiple myeloma with central nervous system relapse
Central nervous system involvement in multiple myeloma is a rare complication but carries a very poor prognosis. We provide a review of current literature, including presentation, treatment and survival data, and describe our experience in a regional hematologic malignancy diagnosis center where, ov...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ferrata Storti Foundation
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327654/ https://www.ncbi.nlm.nih.gov/pubmed/32414852 http://dx.doi.org/10.3324/haematol.2020.248518 |
_version_ | 1783552587336777728 |
---|---|
author | Egan, Philip A. Elder, Patrick T Deighan, W. Ian O’Connor, Sheila J.M. Alexander, H. Denis |
author_facet | Egan, Philip A. Elder, Patrick T Deighan, W. Ian O’Connor, Sheila J.M. Alexander, H. Denis |
author_sort | Egan, Philip A. |
collection | PubMed |
description | Central nervous system involvement in multiple myeloma is a rare complication but carries a very poor prognosis. We provide a review of current literature, including presentation, treatment and survival data, and describe our experience in a regional hematologic malignancy diagnosis center where, over a 15-year period, ten cases were identified. Although the median age of onset, frequently between 50-60 years, is comparatively young, those diagnosed usually have a preceding diagnosis of multiple myeloma and often have had several lines of treatment. We discuss putative underlying factors such as prior treatment and associations including possible risk factors and features suggestive of a distinct biology. Central nervous system involvement may be challenging to diagnose in myeloma, displaying heterogeneous symptoms that can be confounded by neurological symptoms caused by the typical features of myeloma or treatment side-effects. We discuss the clinical features, imaging and laboratory methods used in diagnosis, and highlight the importance of considering this rare complication when neurological symptoms occur at presentation or, more commonly, during the disease pathway. In the absence of clinical trial data to inform an evidence-based approach to treatment, we discuss current and novel treatment options. Finally, we propose the establishment of an International Registry of such cases as the best way to collect and subsequently disseminate presentation, diagnostic and treatment outcome data on this rare complication of multiple myeloma. |
format | Online Article Text |
id | pubmed-7327654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Ferrata Storti Foundation |
record_format | MEDLINE/PubMed |
spelling | pubmed-73276542020-07-10 Multiple myeloma with central nervous system relapse Egan, Philip A. Elder, Patrick T Deighan, W. Ian O’Connor, Sheila J.M. Alexander, H. Denis Haematologica Review Article Central nervous system involvement in multiple myeloma is a rare complication but carries a very poor prognosis. We provide a review of current literature, including presentation, treatment and survival data, and describe our experience in a regional hematologic malignancy diagnosis center where, over a 15-year period, ten cases were identified. Although the median age of onset, frequently between 50-60 years, is comparatively young, those diagnosed usually have a preceding diagnosis of multiple myeloma and often have had several lines of treatment. We discuss putative underlying factors such as prior treatment and associations including possible risk factors and features suggestive of a distinct biology. Central nervous system involvement may be challenging to diagnose in myeloma, displaying heterogeneous symptoms that can be confounded by neurological symptoms caused by the typical features of myeloma or treatment side-effects. We discuss the clinical features, imaging and laboratory methods used in diagnosis, and highlight the importance of considering this rare complication when neurological symptoms occur at presentation or, more commonly, during the disease pathway. In the absence of clinical trial data to inform an evidence-based approach to treatment, we discuss current and novel treatment options. Finally, we propose the establishment of an International Registry of such cases as the best way to collect and subsequently disseminate presentation, diagnostic and treatment outcome data on this rare complication of multiple myeloma. Ferrata Storti Foundation 2020-07 /pmc/articles/PMC7327654/ /pubmed/32414852 http://dx.doi.org/10.3324/haematol.2020.248518 Text en Copyright© 2020 Ferrata Storti Foundation Material published in Haematologica is covered by copyright. All rights are reserved to the Ferrata Storti Foundation. Use of published material is allowed under the following terms and conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode. Copies of published material are allowed for personal or internal use. Sharing published material for non-commercial purposes is subject to the following conditions: https://creativecommons.org/licenses/by-nc/4.0/legalcode, sect. 3. Reproducing and sharing published material for commercial purposes is not allowed without permission in writing from the publisher. |
spellingShingle | Review Article Egan, Philip A. Elder, Patrick T Deighan, W. Ian O’Connor, Sheila J.M. Alexander, H. Denis Multiple myeloma with central nervous system relapse |
title | Multiple myeloma with central nervous system relapse |
title_full | Multiple myeloma with central nervous system relapse |
title_fullStr | Multiple myeloma with central nervous system relapse |
title_full_unstemmed | Multiple myeloma with central nervous system relapse |
title_short | Multiple myeloma with central nervous system relapse |
title_sort | multiple myeloma with central nervous system relapse |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327654/ https://www.ncbi.nlm.nih.gov/pubmed/32414852 http://dx.doi.org/10.3324/haematol.2020.248518 |
work_keys_str_mv | AT eganphilipa multiplemyelomawithcentralnervoussystemrelapse AT elderpatrickt multiplemyelomawithcentralnervoussystemrelapse AT deighanwian multiplemyelomawithcentralnervoussystemrelapse AT oconnorsheilajm multiplemyelomawithcentralnervoussystemrelapse AT alexanderhdenis multiplemyelomawithcentralnervoussystemrelapse |